<code id='BA7A578077'></code><style id='BA7A578077'></style>
    • <acronym id='BA7A578077'></acronym>
      <center id='BA7A578077'><center id='BA7A578077'><tfoot id='BA7A578077'></tfoot></center><abbr id='BA7A578077'><dir id='BA7A578077'><tfoot id='BA7A578077'></tfoot><noframes id='BA7A578077'>

    • <optgroup id='BA7A578077'><strike id='BA7A578077'><sup id='BA7A578077'></sup></strike><code id='BA7A578077'></code></optgroup>
        1. <b id='BA7A578077'><label id='BA7A578077'><select id='BA7A578077'><dt id='BA7A578077'><span id='BA7A578077'></span></dt></select></label></b><u id='BA7A578077'></u>
          <i id='BA7A578077'><strike id='BA7A578077'><tt id='BA7A578077'><pre id='BA7A578077'></pre></tt></strike></i>

          Home / explore / knowledge

          knowledge


          knowledge

          author:knowledge    Page View:9141

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In